Product Description
Mechanisms of Action: LPL Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Ireland | New Zealand | Taiwan | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Samumed Pacific Pty Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Respiratory Distress Syndrome, Newborn|Obstetric Labor, Premature|Acute Respiratory Distress Syndrome|Bronchopulmonary Dysplasia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
Surfactant 1 | P3 |
Completed |
Acute Respiratory Distress Syndrome|Bronchopulmonary Dysplasia|Obstetric Labor, Premature|Respiratory Distress Syndrome, Newborn |
1992-01-01 |